DOI: http://dx.doi.org/10.18203/issn.0019-5359.IndianJMedSci20170486

Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: a placebo controlled study

Reyhaneh Vejdani, Ali Bahari, Abdolrahim Masjedi Zadeh, Mehrdad Azmi, Naser Ebrahimi-Daryani, Ali Asad Hashtroudi, Ali Jafari Mehr, Morteza Abdollahi, Alireza Sayyah, Mohammad Reza Zali, Zohreh Bari, Alireza Bakhshipour

Abstract


Background: The effects of probiotics on ulcerative colitis has still remained a contraversy. The aim of this study was to assess the effects of Lactobacillus casei strain ATCC PTA-3945 in treating ulcerative colitis. Materials and Methods: Thirty four patients with mild to moderately active ulcerative colitis randomly received a probiotic preparation of L. casei strain ATCC PTA-3945 (n = 17) or its placebo (n = 17) plus conventional medical therapy for their active disease. After a maximum of 2 months, remitted patients were again randomised to receive L. casei strain ATCC PTA-3945 or placebo, and also maintained on mesalazine or sulfasalazine tablets for a maximum of 6 months. Results: The numbers of patients achieving remission did not statistically differ between probiotic and placebo groups (82% vs. 76% at intention to treat analysis [P = 1.00], and 100% vs. 81.2% at per-protocol analysis [P = 0.23], respectively). The mean time to clinical remission were 25 days and 32 days in probiotic and placebo groups, respectively (P = 0.11). Relapse rates also did not significantly differ between probiotic and placebo groups (14.3% vs. 26.7% at ITT analysis [P = 0.65] and 16.7% vs. 33.3% [P = 0.64], respectively). Mean time to relapse were 96 days and 74 days in the probiotic and the placebo group, respectively (P = 0.51). Conclusion: The results of this preliminary study showed no significant effect by using L. casei strain ATCC PTA-3945 probiotic in the treatment of ulcerative colitis patients.

 

Keywords


Lactobacillus casei, Probiotic, Ulcerative colitis

Full Text:

PDF

References


Katz S. Update in medical therapy of ulcerative colitis: Newer concepts and therapies. J Clin Gastroenterol 2005;39:557-69.

Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: A systematic review. Neth J Med 2007;65:411-8.

Shanahan F. Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35.

Onderdonk AB, Bronson R, Cisneros R. Comparison of Bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis. Infect Immun 1987;55:835-6.

Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52:79-83.

Binder V. Epidemiology of IBD during the twentieth century: An integrated view. Best Pract Res Clin Gastroenterol 2004;18:463-79.

Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: Dysfunction of GALT and gut bacterial flora (I). Surgeon 2003;1:63-75.

Poxton IR, Brown R, Sawyerr A, Ferguson A. Mucosa-associated bacterial flora of the human colon. J Med Microbiol 1997;46:85-91.

Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: Result of microbial imbalance? Gut 1994;35:658-64.

Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365-78.

Shanahan F. Probiotics in inflammatory bowel disease-therapeutic rationale and role. Adv Drug Deliv Rev 2004;56:809-18.

Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998;42:2-7.

Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999;69:1052S-7S.

Perdigon G, de Jorrat W, de Petrino S, Valerde de Budeguer M. Effect of oral administration of Lactobacillus casei on various biological functions of the host. Food Agric Immunol 1991;3:93-102.

Peran L, Sierra S, Comalada M, Lara-Villoslada F, Bailón E, Nieto A, et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr 2007;97:96-103.

Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8.

Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989;298:82-6.

Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron 2002;92:200-2.

Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 2002;18:435-40.

Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010;16:4145-51.

Hill MJ, Drasar BS. The normal colonic bacterial flora. Gut 1975;16:318-23.

Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984;86:174-93.

Chung KT, Fulk GE, Slein MW. Tryptophanase of fecal flora as a possible factor in the etiology of colon cancer. J Natl Cancer Inst 1975;54:1073-8.

Ganguly NK, Kingham JG, Lloyd B, Lloyd RS, Price CP, Triger DR, et al. Acid hydrolases in monocytes from patients with inflammatory bowel disease, chronic liver disease, and rheumatoid arthritis. Lancet 1978;1:1073-5.

Rhodes JM, Gallimore R, Elias E, Allan RN, Kennedy JF. Faecal mucus degrading glycosidases in ulcerative colitis and Crohn’s disease. Gut 1985;26:761-5.

Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild to moderate ulcerative colitis. Med Sci Monit 2004;10:PI126-31.

Kotake K, Koyama Y, Shida S, Tajima Y, Ishikawa H, Kanazawa K, et al. [Neo-adjuvant chemotherapy with carmofur for colorectal cancer-a multi-institutional randomized controlled study]. Gan To Kagaku Ryoho 2002;29:1917-24.

Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’neil DA, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005;54:242-9.

Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567-74.

Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.

Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999;354:635-9.

Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.

Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of Bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.




 
Home     |     Articles in Press     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     
       
       

Indian Journal of Medical Sciences, Quarterly, published by Medip Academy.     
This is an open-access journal, published articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.

website: www.ijmsweb.com   editorial contact: editor@ijmsweb.com

© Medip Academy. All Rights Reserved.